MX2021004134A - Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. - Google Patents

Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.

Info

Publication number
MX2021004134A
MX2021004134A MX2021004134A MX2021004134A MX2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A
Authority
MX
Mexico
Prior art keywords
chaperone
benzoxazole
sup
compounds useful
related compounds
Prior art date
Application number
MX2021004134A
Other languages
English (en)
Inventor
Ana Maria Cuervo
Evripidis Gavathiotis
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of MX2021004134A publication Critical patent/MX2021004134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos de Fórmula I. (ver formula I) En la presente se definen las variables, por ejemplo, R1-R9, X, e Y. Determinados compuestos y sales de Fórmula I son activos como moduladores de CMA. La descripción proporciona composiciones farmacéuticas que contienen un compuesto de Fórmula I y métodos para tratar trastornos que responden a la modulación de CMA.
MX2021004134A 2018-10-10 2019-10-10 Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. MX2021004134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (1)

Publication Number Publication Date
MX2021004134A true MX2021004134A (es) 2021-07-16

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004134A MX2021004134A (es) 2018-10-10 2019-10-10 Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.

Country Status (11)

Country Link
US (1) US20210387953A1 (es)
EP (1) EP3863755A4 (es)
JP (1) JP2022504650A (es)
KR (1) KR20210082466A (es)
CN (1) CN113195084B (es)
AU (1) AU2019358074A1 (es)
BR (1) BR112021006843A2 (es)
CA (1) CA3115297A1 (es)
IL (1) IL282069A (es)
MX (1) MX2021004134A (es)
WO (1) WO2020077024A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
KR20230000263A (ko) 2021-06-24 2023-01-02 주식회사 엘지화학 합성가스의 제조방법
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469802A (de) * 1966-01-07 1969-03-15 Ciba Geigy Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
DE69628333T2 (de) * 1995-11-17 2004-04-08 Merck & Co., Inc. Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
WO2003048137A1 (en) * 2001-11-30 2003-06-12 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
MX2007000428A (es) * 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3187495A1 (en) * 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR101893997B1 (ko) * 2016-03-17 2018-08-31 연세대학교 산학협력단 NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
BR112019012993A2 (pt) * 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores

Also Published As

Publication number Publication date
WO2020077024A1 (en) 2020-04-16
KR20210082466A (ko) 2021-07-05
CA3115297A1 (en) 2020-04-16
AU2019358074A1 (en) 2021-05-06
IL282069A (en) 2021-05-31
EP3863755A4 (en) 2022-08-03
CN113195084A (zh) 2021-07-30
CN113195084B (zh) 2024-04-09
US20210387953A1 (en) 2021-12-16
EP3863755A1 (en) 2021-08-18
JP2022504650A (ja) 2022-01-13
BR112021006843A2 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
MX2021004134A (es) Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ730808A (en) Immunoregulatory agents
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EP4316591A3 (en) Oxysterols and methods of use thereof
CR20210627A (es) Derivados de benzisoxazol sulfonimada
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MD3411411T2 (ro) Derivați de 1H-indazol-3-carboxamidă și compuși înrudiți în calitate de inhibitori ai factorului D pentru tratamentul bolilor caracterizate prin activitate aberantă a sistemului complementului, cum ar fi, de exemplu, tulburări imunologice
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2019175799A3 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.